Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
This study will examine the safety and efficacy of pegaptanib sodium in Japanese patients
with wet-type age-related macular degeneration (AMD), who benefit further treatment and who
want to continue the treatment after completion of the preceding study (A5751010).